1	3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	Identified	_	_	VBN	_	_	_	_	_
2	mechanisms	_	_	NNS	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	target	_	_	NN	_	_	_	_	_
5	molecule	_	_	NN	_	_	_	_	_
6	elevation	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	CKD	_	_	NN	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	either	_	_	CC	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	decrease	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	renal	_	_	JJ	_	_	_	_	_
16	excretion	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	an	_	_	DT	_	_	_	_	_
19	increase	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	endogenous	_	_	JJ	_	_	_	_	_
22	production	_	_	NN	_	_	_	_	_
23	or	_	_	CC	_	_	_	_	_
24	both	_	_	DT	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	TMAO	_	_	NNP	_	_	_	_	_
4	levels	_	_	NNS	_	_	_	_	_
5	could	_	_	MD	_	_	_	_	_
6	result	_	_	VB	_	_	_	_	_
7	from	_	_	IN	_	_	_	_	_
8	variations	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	production	_	_	NN	_	_	_	_	_
11	levels	_	_	NNS	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	including	_	_	VBG	_	_	_	_	_
14	dietary	_	_	JJ	_	_	_	_	_
15	precursor	_	_	NN	_	_	_	_	_
16	intake	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	TMA	_	_	NN	_	_	_	_	_
19	endogenous	_	_	JJ	_	_	_	_	_
20	production	_	_	NN	_	_	_	_	_
21	from	_	_	IN	_	_	_	_	_
22	gut	_	_	NN	_	_	_	_	_
23	microbiota	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	TMA	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	TMAO	_	_	NN	_	_	_	_	_
28	intestinal	_	_	JJ	_	_	_	_	_
29	absorption	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	FMO3	_	_	NN	_	_	_	_	_
33	enzymatic	_	_	JJ	_	_	_	_	_
34	activity	_	_	NN	_	_	_	_	_
35	)	_	_	-RRB-	_	_	_	_	_
36	or	_	_	CC	_	_	_	_	_
37	from	_	_	IN	_	_	_	_	_
38	its	_	_	PRP$	_	_	_	_	_
39	renal	_	_	JJ	_	_	_	_	_
40	excretion	_	_	NN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	therefore	_	_	RB	_	_	_	_	_
5	designed	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	assess	_	_	VB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	exact	_	_	JJ	_	_	_	_	_
10	changes	_	_	NNS	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	TMAO	_	_	NNP	_	_	_	_	_
13	values	_	_	NNS	_	_	_	_	_
14	according	_	_	VBG	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	CKD	_	_	NNP	_	_	_	_	_
17	stages	_	_	NNS	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	determined	_	_	VBN	_	_	_	_	_
20	by	_	_	IN	_	_	_	_	_
21	gold	_	_	NN	_	_	_	_	_
22	standard	_	_	JJ	_	_	_	_	_
23	measurements	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	GFR	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	its	_	_	PRP$	_	_	_	_	_
28	potential	_	_	JJ	_	_	_	_	_
29	modifications	_	_	NNS	_	_	_	_	_
30	during	_	_	IN	_	_	_	_	_
31	renal	_	_	JJ	_	_	_	_	_
32	metabolism	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	present	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	confirmed	_	_	VBD	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	TMAO	_	_	NNP	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	increased	_	_	VBN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	CKD	_	_	NNP	_	_	_	_	_
14	based	_	_	VBN	_	_	_	_	_
15	on	_	_	IN	_	_	_	_	_
16	an	_	_	DT	_	_	_	_	_
17	inverse	_	_	JJ	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	although	_	_	IN	_	_	_	_	_
20	weak	_	_	JJ	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	correlation	_	_	NN	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	r2	_	_	NN	_	_	_	_	_
25	=	_	_	SYM	_	_	_	_	_
26	0.388	_	_	CD	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	between	_	_	IN	_	_	_	_	_
29	plasma	_	_	NN	_	_	_	_	_
30	TMAO	_	_	NNP	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	mGFR	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Surprisingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	all	_	_	DT	_	_	_	_	_
5	stages	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	CKD	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	we	_	_	PRP	_	_	_	_	_
10	did	_	_	VBD	_	_	_	_	_
11	not	_	_	RB	_	_	_	_	_
12	find	_	_	VB	_	_	_	_	_
13	any	_	_	DT	_	_	_	_	_
14	correlation	_	_	NN	_	_	_	_	_
15	between	_	_	IN	_	_	_	_	_
16	TMAO	_	_	NNP	_	_	_	_	_
17	levels	_	_	NNS	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	its	_	_	PRP$	_	_	_	_	_
20	precursors	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	except	_	_	IN	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	weak	_	_	JJ	_	_	_	_	_
25	correlation	_	_	NN	_	_	_	_	_
26	with	_	_	IN	_	_	_	_	_
27	carnitine	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Measured	_	_	VBN	_	_	_	_	_
2	clearances	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	TMAO	_	_	NNP	_	_	_	_	_
5	showed	_	_	VBD	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	complete	_	_	JJ	_	_	_	_	_
8	renal	_	_	JJ	_	_	_	_	_
9	excretion	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	TMAO	_	_	NNP	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	glomerular	_	_	NN	_	_	_	_	_
14	filtration	_	_	NN	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	steady	_	_	JJ	_	_	_	_	_
18	FE	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	105	_	_	CD	_	_	_	_	_
21	%	_	_	NN	_	_	_	_	_
22	during	_	_	IN	_	_	_	_	_
23	CKD	_	_	NNP	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	regardless	_	_	RB	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	stage	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Unlike	_	_	IN	_	_	_	_	_
2	previous	_	_	JJ	_	_	_	_	_
3	studies	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	reported	_	_	VBD	_	_	_	_	_
7	no	_	_	DT	_	_	_	_	_
8	evidence	_	_	NN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	effective	_	_	JJ	_	_	_	_	_
11	contribution	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	tubular	_	_	JJ	_	_	_	_	_
14	excretion	_	_	NN	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	reabsorption	_	_	NN	_	_	_	_	_
17	during	_	_	IN	_	_	_	_	_
18	renal	_	_	JJ	_	_	_	_	_
19	clearance	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	TMAO	_	_	NNP	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	hemodialysis	_	_	NN	_	_	_	_	_
3	patients	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	confirmed	_	_	VBD	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	greater	_	_	JJR	_	_	_	_	_
9	increase	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	TMAO	_	_	NNP	_	_	_	_	_
12	even	_	_	RB	_	_	_	_	_
13	though	_	_	IN	_	_	_	_	_
14	FR	_	_	NNP	_	_	_	_	_
15	was	_	_	VBD	_	_	_	_	_
16	similar	_	_	JJ	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	that	_	_	DT	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	urea	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	investigated	_	_	VBD	_	_	_	_	_
4	for	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	first	_	_	JJ	_	_	_	_	_
7	time	_	_	NN	_	_	_	_	_
8	TMAO	_	_	NN	_	_	_	_	_
9	levels	_	_	NNS	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	all	_	_	DT	_	_	_	_	_
12	stages	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	CKD	_	_	NN	_	_	_	_	_
15	using	_	_	VBG	_	_	_	_	_
16	gold	_	_	NN	_	_	_	_	_
17	standard	_	_	JJ	_	_	_	_	_
18	measures	_	_	NNS	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	GFR	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Results	_	_	NNS	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	TMAO	_	_	NNP	_	_	_	_	_
4	plasma	_	_	NN	_	_	_	_	_
5	concentrations	_	_	NNS	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	CKD	_	_	NNP	_	_	_	_	_
8	were	_	_	VBD	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	good	_	_	JJ	_	_	_	_	_
11	accordance	_	_	NN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	previous	_	_	JJ	_	_	_	_	_
14	studies	_	_	NNS	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Median	_	_	JJ	_	_	_	_	_
2	TMAO	_	_	NN	_	_	_	_	_
3	plasma	_	_	NN	_	_	_	_	_
4	levels	_	_	NNS	_	_	_	_	_
5	found	_	_	VBN	_	_	_	_	_
6	herein	_	_	RB	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	similar	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	those	_	_	DT	_	_	_	_	_
11	published	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	Stubbs	_	_	NNP	_	_	_	_	_
14	et	_	_	FW	_	_	_	_	_
15	al.	_	_	FW	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	2015	_	_	CD	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	even	_	_	RB	_	_	_	_	_
20	though	_	_	IN	_	_	_	_	_
21	their	_	_	PRP$	_	_	_	_	_
22	data	_	_	NNS	_	_	_	_	_
23	was	_	_	VBD	_	_	_	_	_
24	based	_	_	VBN	_	_	_	_	_
25	on	_	_	IN	_	_	_	_	_
26	estimated	_	_	VBN	_	_	_	_	_
27	GFR	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Another	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	reported	_	_	VBD	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	negative	_	_	JJ	_	_	_	_	_
6	correlation	_	_	NN	_	_	_	_	_
7	between	_	_	IN	_	_	_	_	_
8	TMAO	_	_	NNP	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	mGFR	_	_	NNP	_	_	_	_	_
11	but	_	_	CC	_	_	_	_	_
12	both	_	_	DT	_	_	_	_	_
13	data	_	_	NNS	_	_	_	_	_
14	sets	_	_	NNS	_	_	_	_	_
15	were	_	_	VBD	_	_	_	_	_
16	restricted	_	_	VBN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	CKD	_	_	NN	_	_	_	_	_
19	stages	_	_	NNS	_	_	_	_	_
20	3	_	_	CD	_	_	_	_	_
21	or	_	_	CC	_	_	_	_	_
22	more	_	_	RBR	_	_	_	_	_
23	severe	_	_	JJ	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	best	_	_	JJS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	our	_	_	PRP$	_	_	_	_	_
6	knowledge	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	no	_	_	DT	_	_	_	_	_
9	study	_	_	NN	_	_	_	_	_
10	has	_	_	VBZ	_	_	_	_	_
11	performed	_	_	VBN	_	_	_	_	_
12	urinary	_	_	JJ	_	_	_	_	_
13	clearance	_	_	NN	_	_	_	_	_
14	measures	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	TMAO	_	_	NNP	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	CKD	_	_	NNP	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Previously	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	Hai	_	_	NNP	_	_	_	_	_
4	et	_	_	FW	_	_	_	_	_
5	al.	_	_	FW	_	_	_	_	_
6	published	_	_	VBN	_	_	_	_	_
7	TMAO	_	_	NN	_	_	_	_	_
8	clearances	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	control	_	_	NN	_	_	_	_	_
11	subjects	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	reporting	_	_	VBG	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	higher	_	_	JJR	_	_	_	_	_
16	clearance	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	TMAO	_	_	NN	_	_	_	_	_
19	compared	_	_	VBN	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	creatinine	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	suggesting	_	_	VBG	_	_	_	_	_
24	an	_	_	DT	_	_	_	_	_
25	active	_	_	JJ	_	_	_	_	_
26	secretion	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	TMAO	_	_	NNP	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Due	_	_	JJ	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	its	_	_	PRP$	_	_	_	_	_
4	low	_	_	JJ	_	_	_	_	_
5	molecular	_	_	JJ	_	_	_	_	_
6	weight	_	_	NN	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	75	_	_	CD	_	_	_	_	_
9	Da	_	_	NN	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	soluble	_	_	JJ	_	_	_	_	_
13	non	_	_	CC	_	_	_	_	_
14	ionizable	_	_	JJ	_	_	_	_	_
15	nature	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	minimal	_	_	JJ	_	_	_	_	_
19	protein-bound	_	_	JJ	_	_	_	_	_
20	fraction	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	we	_	_	PRP	_	_	_	_	_
23	consider	_	_	VBP	_	_	_	_	_
24	TMAO	_	_	NNP	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	be	_	_	VB	_	_	_	_	_
27	entirely	_	_	RB	_	_	_	_	_
28	filtered	_	_	VBN	_	_	_	_	_
29	through	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	glomerular	_	_	JJ	_	_	_	_	_
32	basement	_	_	NN	_	_	_	_	_
33	membrane	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	which	_	_	WDT	_	_	_	_	_
36	is	_	_	VBZ	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	main	_	_	JJ	_	_	_	_	_
39	known	_	_	VBN	_	_	_	_	_
40	elimination	_	_	NN	_	_	_	_	_
41	route	_	_	NN	_	_	_	_	_
42	for	_	_	IN	_	_	_	_	_
43	TMAO	_	_	NNP	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	showed	_	_	VBD	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	likely	_	_	RB	_	_	_	_	_
6	complete	_	_	JJ	_	_	_	_	_
7	TMAO	_	_	NNP	_	_	_	_	_
8	glomerular	_	_	JJ	_	_	_	_	_
9	filtration	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	steady	_	_	JJ	_	_	_	_	_
13	FE	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	TMAO	_	_	NNP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	regardless	_	_	RB	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	CKD	_	_	NN	_	_	_	_	_
20	stages	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	TMAO	_	_	NNP	_	_	_	_	_
2	clearance	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	similar	_	_	JJ	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	that	_	_	DT	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	mGFR	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	higher	_	_	JJR	_	_	_	_	_
11	than	_	_	IN	_	_	_	_	_
12	that	_	_	DT	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	urea	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	lower	_	_	JJR	_	_	_	_	_
18	than	_	_	IN	_	_	_	_	_
19	that	_	_	DT	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	creatinine	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	suggesting	_	_	VBG	_	_	_	_	_
24	that	_	_	IN	_	_	_	_	_
25	TMAO	_	_	NNP	_	_	_	_	_
26	is	_	_	VBZ	_	_	_	_	_
27	neither	_	_	RB	_	_	_	_	_
28	secreted	_	_	VBN	_	_	_	_	_
29	as	_	_	IN	_	_	_	_	_
30	creatinine	_	_	NN	_	_	_	_	_
31	nor	_	_	CC	_	_	_	_	_
32	reabsorbed	_	_	VBN	_	_	_	_	_
33	as	_	_	IN	_	_	_	_	_
34	urea	_	_	NN	_	_	_	_	_
35	by	_	_	IN	_	_	_	_	_
36	renal	_	_	JJ	_	_	_	_	_
37	tubules	_	_	NNS	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	however	_	_	RB	_	_	_	_	_
3	cannot	_	_	MD	_	_	_	_	_
4	exclude	_	_	VB	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	secretion	_	_	NN	_	_	_	_	_
8	rate	_	_	NN	_	_	_	_	_
9	exactly	_	_	RB	_	_	_	_	_
10	matched	_	_	VBD	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	reabsorption	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	TMAO	_	_	NNP	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	high	_	_	JJ	_	_	_	_	_
4	fractional	_	_	JJ	_	_	_	_	_
5	reabsorption	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	sodium	_	_	NN	_	_	_	_	_
8	indicates	_	_	VBZ	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	study	_	_	NN	_	_	_	_	_
11	participants	_	_	NNS	_	_	_	_	_
12	had	_	_	VBD	_	_	_	_	_
13	no	_	_	DT	_	_	_	_	_
14	tubular	_	_	JJ	_	_	_	_	_
15	impairment	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	which	_	_	WDT	_	_	_	_	_
18	reinforces	_	_	VBZ	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	validity	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	these	_	_	DT	_	_	_	_	_
23	data	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	IQR	_	_	NNP	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	TMAO	_	_	NNP	_	_	_	_	_
7	FE	_	_	NNP	_	_	_	_	_
8	showed	_	_	VBD	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	some	_	_	DT	_	_	_	_	_
11	patients	_	_	NNS	_	_	_	_	_
12	exhibited	_	_	VBD	_	_	_	_	_
13	higher	_	_	JJR	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	lower	_	_	JJR	_	_	_	_	_
16	clearances	_	_	NNS	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	TMAO	_	_	NNP	_	_	_	_	_
19	compared	_	_	VBN	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	mGFR	_	_	NNP	_	_	_	_	_
22	;	_	_	:	_	_	_	_	_
23	especially	_	_	RB	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	control	_	_	NN	_	_	_	_	_
27	group	_	_	NN	_	_	_	_	_
28	where	_	_	WRB	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	median	_	_	JJ	_	_	_	_	_
31	FE	_	_	NNP	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	TMAO	_	_	NNP	_	_	_	_	_
34	was	_	_	VBD	_	_	_	_	_
35	103	_	_	CD	_	_	_	_	_
36	%	_	_	NN	_	_	_	_	_
37	[	_	_	-LRB-	_	_	_	_	_
38	IQR	_	_	NN	_	_	_	_	_
39	55	_	_	CD	_	_	_	_	_
40	–	_	_	TO	_	_	_	_	_
41	144	_	_	CD	_	_	_	_	_
42	]	_	_	-RRB-	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	dispersion	_	_	NN	_	_	_	_	_
3	could	_	_	MD	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	explained	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	several	_	_	JJ	_	_	_	_	_
8	factors	_	_	NNS	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	First	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	urinary	_	_	JJ	_	_	_	_	_
4	clearance	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	TMAO	_	_	NNP	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	not	_	_	RB	_	_	_	_	_
9	assessed	_	_	VBN	_	_	_	_	_
10	at	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	exact	_	_	JJ	_	_	_	_	_
13	same	_	_	JJ	_	_	_	_	_
14	time	_	_	NN	_	_	_	_	_
15	points	_	_	NNS	_	_	_	_	_
16	than	_	_	IN	_	_	_	_	_
17	mGFR	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	measured	_	_	VBN	_	_	_	_	_
20	by	_	_	IN	_	_	_	_	_
21	inulin	_	_	NN	_	_	_	_	_
22	or	_	_	CC	_	_	_	_	_
23	iohexol	_	_	NN	_	_	_	_	_
24	clearance	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Second	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	variability	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	TMAO	_	_	NN	_	_	_	_	_
7	excretion	_	_	NN	_	_	_	_	_
8	could	_	_	MD	_	_	_	_	_
9	also	_	_	RB	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	related	_	_	VBN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	amount	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	ingested	_	_	VBN	_	_	_	_	_
17	TMA	_	_	NN	_	_	_	_	_
18	precursors	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	unfortunately	_	_	RB	_	_	_	_	_
3	did	_	_	VBD	_	_	_	_	_
4	not	_	_	RB	_	_	_	_	_
5	administer	_	_	VB	_	_	_	_	_
6	standardized	_	_	VBN	_	_	_	_	_
7	meals	_	_	NNS	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	avoid	_	_	VB	_	_	_	_	_
10	this	_	_	DT	_	_	_	_	_
11	bias	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Yet	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	did	_	_	VBD	_	_	_	_	_
5	not	_	_	RB	_	_	_	_	_
6	find	_	_	VB	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	significant	_	_	JJ	_	_	_	_	_
9	correlation	_	_	NN	_	_	_	_	_
10	between	_	_	IN	_	_	_	_	_
11	plasma	_	_	NN	_	_	_	_	_
12	levels	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	TMAO	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	total	_	_	JJ	_	_	_	_	_
17	protein	_	_	NN	_	_	_	_	_
18	intake	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	several	_	_	JJ	_	_	_	_	_
4	studies	_	_	NNS	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	animal	_	_	NN	_	_	_	_	_
7	or	_	_	CC	_	_	_	_	_
8	cellular	_	_	JJ	_	_	_	_	_
9	models	_	_	NNS	_	_	_	_	_
10	have	_	_	VBP	_	_	_	_	_
11	shown	_	_	VBN	_	_	_	_	_
12	involvement	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	tubular	_	_	JJ	_	_	_	_	_
15	transporters	_	_	NNS	_	_	_	_	_
16	such	_	_	JJ	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	organic	_	_	JJ	_	_	_	_	_
19	cation	_	_	NN	_	_	_	_	_
20	transporter	_	_	NN	_	_	_	_	_
21	2	_	_	CD	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	OCT2	_	_	CD	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	TMAO	_	_	NNP	_	_	_	_	_
27	cellular	_	_	JJ	_	_	_	_	_
28	uptake	_	_	NN	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	efflux	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	however	_	_	RB	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	has	_	_	VBZ	_	_	_	_	_
6	not	_	_	RB	_	_	_	_	_
7	been	_	_	VBN	_	_	_	_	_
8	confirmed	_	_	VBN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	humans	_	_	NNS	_	_	_	_	_
11	unlike	_	_	IN	_	_	_	_	_
12	what	_	_	WP	_	_	_	_	_
13	has	_	_	VBZ	_	_	_	_	_
14	been	_	_	VBN	_	_	_	_	_
15	previously	_	_	RB	_	_	_	_	_
16	described	_	_	VBN	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	creatinine	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	observed	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	elevation	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	TMAO	_	_	NNP	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	mostly	_	_	RB	_	_	_	_	_
9	due	_	_	JJ	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	decrease	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	mGFR	_	_	NN	_	_	_	_	_
15	rather	_	_	RB	_	_	_	_	_
16	than	_	_	IN	_	_	_	_	_
17	tubular	_	_	JJ	_	_	_	_	_
18	dysfunction	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	line	_	_	NN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	another	_	_	DT	_	_	_	_	_
8	recent	_	_	JJ	_	_	_	_	_
9	study	_	_	NN	_	_	_	_	_
10	reporting	_	_	VBG	_	_	_	_	_
11	that	_	_	IN	_	_	_	_	_
12	urinary	_	_	JJ	_	_	_	_	_
13	TMAO/creatinine	_	_	NN	_	_	_	_	_
14	ratios	_	_	NNS	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	used	_	_	VBN	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	surrogate	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	TMAO	_	_	NN	_	_	_	_	_
22	excretion	_	_	NN	_	_	_	_	_
23	rate	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	were	_	_	VBD	_	_	_	_	_
26	not	_	_	RB	_	_	_	_	_
27	significantly	_	_	RB	_	_	_	_	_
28	different	_	_	JJ	_	_	_	_	_
29	between	_	_	IN	_	_	_	_	_
30	control	_	_	NN	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	CKD	_	_	NN	_	_	_	_	_
33	subjects	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_

